Hypoxia News and Research

RSS

Hypoxia is a condition in which there is a decrease in the oxygen supply to a tissue. In cancer treatment, the level of hypoxia in a tumor may help predict the response of the tumor to the treatment.

Doctor explores link between lack of oxygen and inflammation in patients undergoing surgery

When the body is deprived of oxygen during a major surgery, the kidneys, heart muscles or lungs can be injured as a result. The problem is that lack of oxygen can lead to inflammation.

19 Feb 2011

Two studies investigate frontiers of islet cell transplantation for treating diabetes

Two studies published in the current issue of Cell Transplantation investigate frontiers of islet cell transplantation for treating diabetes. Researchers in Milan, Italy re-examine the role of bone marrow stem cells in diabetic therapy and islet cell regeneration and Canadian researchers offer improved strategies for optimizing pancreatic islet culture in vitro.

18 Feb 2011

FDA, Threshold enter agreement on SPA for TH-302 Phase 3 trial in patients with soft tissue sarcoma

Threshold Pharmaceuticals, Inc. today announced that the Company reached agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment for a Phase 3 randomized trial of TH-302 in patients with soft tissue sarcoma.

17 Feb 2011

Study: Overexpression of EZH2 protein promotes breast cancer progression

An essential protein for normal stem cell renewal also promotes the growth of breast cancer stem cells when it's overproduced in those cells, researchers at The University of Texas MD Anderson Cancer Center report in the February edition of Cancer Cell.

16 Feb 2011

Extensive, reversible changes in heart take place when exposed to low oxygen levels

From the highest mountaintop comes a new research report in the FASEB Journal that gets to the bottom of what happens to the hearts of people when exposed to low-levels of oxygen, such as those on Mount Everest or in the intensive care unit of a hospital.

1 Feb 2011

Phase III study shows tapentadol ER relieves chronic pain associated with DPN

New research has been published indicating that patients suffering from a painful complication of diabetes may experience a significant improvement in their pain as measured by a pain intensity scale when using an investigational pain medication.

29 Jan 2011

Glioblastoma's molecular flexibility helps resist nearly all treatment efforts

Glioblastoma, the most common and lethal form of brain cancer and the disease that killed Massachusetts Senator Ted Kennedy, resists nearly all treatment efforts, even when attacked simultaneously on several fronts. One explanation can be found in the tumor cells' unexpected flexibility, discovered researchers at the Salk Institute for Biological Studies.

25 Jan 2011

University of California study may shed light on human ability to adapt hypoxia

In an important study that may shed light on human ability to adapt to hypoxia, or inadequate levels of oxygen, researchers at the University of California, San Diego School of Medicine have proven that the genome of flies exposed to long-term hypoxia are changed to permanently affect gene expression.

24 Jan 2011

Threshold reports positive results from TH-302 Phase 1/2 clinical trial in pancreatic cancer

Threshold Pharmaceuticals, Inc. today announced updated Phase 1/2 clinical trial results related to the Company's clinical stage hypoxia-activated prodrug, TH-302. The results were presented at the ASCO Gastro Intestinal Cancers Symposium that took place in San Francisco from January 20-22, 2011.

24 Jan 2011

Spectrum submits Post Approval Supplement for removal of bioscan requirement for Indium-111 ZEVALIN

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that on Thursday, January 20, 2011, it submitted a Post Approval Supplement containing data supporting the removal of the Indium-111 ZEVALIN® pre-treatment imaging evaluation, more commonly referred to as the "bioscan" requirement.

24 Jan 2011

Living at higher altitudes may increase risk for suicide

Twenty years of mortality data from counties across the United States led to the striking discovery that living at higher altitudes may be a risk factor for suicide, according to a provocative study published online ahead of print in High Altitude Medicine & Biology, a peer-reviewed journal published by Mary Ann Liebert, Inc. The article is attached.

14 Jan 2011

Dendreon provides U.S. commercialization and European strategy updates for PROVENGE

Dendreon Corporation today announced several updates regarding the U.S. commercialization of PROVENGE® (sipuleucel-T), the European strategy for PROVENGE, and progress on its pipeline.

7 Jan 2011

Turns mortal heart attacks into non-mortal heart attacks -- NIH study

Three weeks of oral resveratrol or Longevinex- ingestion prior to an induced heart attack returned microRNA activity close to their pre-event levels in excised animal hearts. Among thousands of microRNA's studied, just six were attributed to exerting the majority of the gene-switching effects measured in the animal heart study - four microRNA optimally regulated by Longevinex- and two optimally by plain resveratrol.

28 Dec 2010

Researchers identify class of drugs that can promote RBC formation in anemic patients

By determining how corticosteroids act to promote red blood cell progenitor formation, Whitehead Institute researchers have identified a class of drugs that may be beneficial in anemias, including those resulting from trauma, sepsis, malaria, kidney dialysis, and chemotherapy.

22 Dec 2010

Enzon in collaboration with NCI initiates EZN-2968, EZN-2208 Phase I studies for arresting tumor growth

Enzon Pharmaceuticals, today announced the initiation of Phase I clinical studies, in collaboration with the National Cancer Institute, for two of the Company's novel oncology product candidates, EZN-2968 and EZN-2208 (PEG-SN38).

16 Dec 2010

Scientists identify signaling pathway and receptor for thymosin beta 4

RegeneRx Biopharmaceuticals, Inc. nnounced that scientists have identified a long sought-after extracellular signaling pathway and receptor for thymosin beta 4 (Tβ4). The observation that Tβ4 increases cell surface ATP (energy produced by cells), could explain its ability to protect and regenerate tissue after ischemic injury and hypoxia (oxygen deficiency).

30 Nov 2010

FG-2216 drug offers new treatment option for kidney disease-related anemia

A new drug called FG-2216 can stimulate production of the hormone erythropoietin (EPO) in dialysis patients—possibly offering a new approach to treatment of kidney disease-related anemia, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).

30 Nov 2010

FibroGen to present FG-4592 phase 2a study of patients with stage 3-4 Chronic Kidney Disease and anemia

FibroGen, Inc., today announced that new data from a phase 2a study of patients with stage 3-4 Chronic Kidney Disease and anemia will be presented demonstrating that its first-in-class, investigational oral anemia therapy FG-4592 works differently than erythropoiesis stimulating agents (ESAs) to increase hemoglobin.

19 Nov 2010

ZIOPHARM announces data on darinaparsin efficacy for solid tumors at EORTC-NCI-AACR Symposium

ZIOPHARM Oncology, Inc. announced today important new preclinical data on the efficacy of darinaparsin (ZinaparTM, or ZIO-101) in various solid tumor models delivered at the EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics being held in Berlin, Germany.

19 Nov 2010

Threshold Pharmaceuticals announces results on TH-302 prodrug for cancers at EORTC-NCI-AACR Symposium

Threshold Pharmaceuticals, Inc. today announced clinical trial results related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. The results were presented at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics taking place in Berlin, Germany from November 16 to19, 2010.

19 Nov 2010

Hypoxia News and Research

Further Reading

Doctor explores link between lack of oxygen and inflammation in patients undergoing surgery

Two studies investigate frontiers of islet cell transplantation for treating diabetes

FDA, Threshold enter agreement on SPA for TH-302 Phase 3 trial in patients with soft tissue sarcoma

Study: Overexpression of EZH2 protein promotes breast cancer progression

Extensive, reversible changes in heart take place when exposed to low oxygen levels

Phase III study shows tapentadol ER relieves chronic pain associated with DPN

Glioblastoma's molecular flexibility helps resist nearly all treatment efforts

University of California study may shed light on human ability to adapt hypoxia

Threshold reports positive results from TH-302 Phase 1/2 clinical trial in pancreatic cancer

Spectrum submits Post Approval Supplement for removal of bioscan requirement for Indium-111 ZEVALIN

Living at higher altitudes may increase risk for suicide

Dendreon provides U.S. commercialization and European strategy updates for PROVENGE

Turns mortal heart attacks into non-mortal heart attacks -- NIH study

Researchers identify class of drugs that can promote RBC formation in anemic patients

Enzon in collaboration with NCI initiates EZN-2968, EZN-2208 Phase I studies for arresting tumor growth

Scientists identify signaling pathway and receptor for thymosin beta 4

FG-2216 drug offers new treatment option for kidney disease-related anemia

FibroGen to present FG-4592 phase 2a study of patients with stage 3-4 Chronic Kidney Disease and anemia

ZIOPHARM announces data on darinaparsin efficacy for solid tumors at EORTC-NCI-AACR Symposium

Threshold Pharmaceuticals announces results on TH-302 prodrug for cancers at EORTC-NCI-AACR Symposium

Lab Matters host Harriet Gould on building a more connected lab community

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

Latest News